IL6 and neoplasm: In parallel, IMiDs, including thalidomide, lenalidomide, and pomalidomide, are also considered immunotherapeutic agents due to their capacity to stimulate T and NK lymphocytes, inhibit angiogenesis, and modulate cytokine secretion (e.g., IL-6 and TNF-α) that drives tumor proliferation [97,99].